Brussels Stock Exchange:HYL

<!-- Name:DistributionId Value:1000798305 --> <!-- Name:NewsArchiveTags Value:MyWeb --> <!-- Name:NewsArchiveOrgTags Value:MyWeb#My…

Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part of them needing direct treatment during and/or after their hospital stay1…

Hyloris Pharmaceuticals Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis Hyloris targets a condition that affects up to 7% of the global adult population without…